TL;DR
This large, multinational study reveals that nearly half of patients undergoing radical cystectomy for bladder cancer have anemia before surgery, and this condition is significantly associated with worse perioperative and long-term oncological outcomes. The findings highlight a critical need for systematic preoperative anemia management in this patient population.
What Problem Does This Paper Address?
Radical cystectomy is a major surgery for bladder cancer, and patients undergoing this procedure often have other health issues. One common issue is anemia, or low red blood cell count. While previous smaller studies have hinted that anemia might be linked to worse outcomes after cystectomy, these findings were limited by their single-center nature and sample size, making it hard to draw firm conclusions. The exact prevalence of preoperative anemia in this specific patient group, the factors contributing to it, and its precise impact on both immediate surgical recovery and long-term cancer survival across diverse healthcare settings remained poorly understood. This paper aims to fill that gap by investigating these questions in a large, multicenter cohort.
Methods
This study employed a retrospective observational design, analyzing data from 4886 patients who underwent radical cystectomy for nonmetastatic bladder cancer across 28 centers in 13 countries between 1990 and 2021. The researchers collected detailed patient characteristics, medical history, treatment regimens, and survival outcomes from medical records.
Key analytical approaches included:
- Multivariable regression models: Used to identify predictors of preoperative hemoglobin (Hb) levels and the need for postoperative blood transfusions.
- Kaplan-Meier analysis: Employed for unadjusted survival analysis to compare outcomes between anemic and non-anemic patients.
- Cox proportional hazards regression: Utilized to assess the association between preoperative Hb levels and oncological outcomes (all-cause mortality, cancer-specific mortality, and disease relapse), adjusting for potential confounders.
- Logistic regression: Used to analyze the association between preoperative Hb levels and 90-day mortality.
The study adhered to the Declaration of Helsinki and Good Clinical Practice guidelines, with data anonymized to protect patient privacy.
Datasets
The study utilized a retrospective dataset compiled from the medical records of 4886 patients across 28 participating institutions in 13 countries. This dataset included information collected over a long period (1990-2021), encompassing various aspects of patient care from diagnosis through long-term follow-up. No new datasets or benchmarks were introduced; the study relied on existing patient data.
Key Insights and Ideas
- Anemia is a widespread problem: The sheer prevalence of anemia (around 50% of patients) before such a major surgery is a significant finding, suggesting it's not an isolated issue but a common comorbidity.
- Under-treatment is rampant: A striking observation is that a large majority (73%) of anemic patients received no specific interventions to boost their hemoglobin levels. This points to a missed opportunity for improving patient care.
- Anemia is a strong predictor of poor outcomes: Beyond just being present, anemia is shown to be independently associated with worse survival and increased complications. This elevates it from a simple lab finding to a critical prognostic factor.
- Multiple factors contribute to anemia: The study identified several predictors, including older age, neoadjuvant chemotherapy, and higher tumor stage, which can help clinicians identify at-risk patients proactively.
- Robotic surgery's potential benefit in anemia: While preliminary, the finding that robotic-assisted surgery was associated with fewer transfusions, especially in the context of anemia, opens an interesting avenue for further investigation.
Key Results
- Prevalence: Approximately 44% of women and 48% of men had preoperative anemia based on WHO thresholds.
- Treatment Gap: Among anemic patients, only about 25% received any form of Hb optimization, with iron supplementation used in only 4%.
- Survival Impact: Patients with preoperative Hb <130 g/l had significantly worse 5-year overall survival (44% vs. 65%), cancer-specific survival (64% vs. 78%), and recurrence-free survival (67% vs. 75%).
- Prognostic Significance: Higher preoperative Hb levels were independently associated with lower all-cause mortality (HR: 0.99), cancer-specific mortality (HR: 0.99), and disease relapse (HR: 0.99) after adjusting for confounders.
- 90-day Mortality: Higher ECOG score, older age, blood transfusions, and higher tumor stage were independently associated with significantly higher 90-day mortality.
- Blood Transfusions: Higher tumor stage and older age increased the likelihood of needing postoperative blood transfusions, while higher Hb levels before TURBT and cystectomy, neoadjuvant therapy, and robotic surgery reduced this need.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Nature: This introduces potential selection bias and the possibility of unmeasured confounding factors (e.g., specific perioperative complications not captured).
- Long Study Period: Changes in surgical techniques and perioperative care over the 1990-2021 period could influence outcomes. The lower rate of neoadjuvant chemotherapy use in earlier years is noted as an example.
- Variability in Practice: Differences in practice patterns across centers and regions might affect generalizability.
- Lack of Specific Anemia Causes: Detailed information on the specific causes of anemia (e.g., iron deficiency, chronic disease) was not available, limiting deeper insights into management.
- No Direct Assessment of Correction: The study shows an association between anemia and outcomes but does not directly prove that correcting anemia before surgery improves survival.
Future Work: The authors strongly recommend:
- Prospective Studies: To evaluate the impact of standardized preoperative anemia management protocols on outcomes.
- Molecular Mechanisms: Investigating how anemia influences poorer oncological outcomes at a molecular level.
- Cost-Effectiveness Analyses: To guide clinical practice by assessing the economic value of different anemia management strategies.
- Further research into interventions: To clarify whether interventions like EPO and vitamin B12 are causally linked to worse outcomes or simply reflect the severity of anemia in patients receiving them.
Summary updated